Hapytab Tablet (Extended Release)

Hapytab Tablet (Extended Release) 50 mg the major active metabolite of venlafaxine, is an antidepressant from the serotonin norepinephrine reuptake inhibitor (SNRI) class. Hapytab Tablet (Extended Release) 50 mg may be used to treat major depressive disorder. It is formulated as an extended release tablet.

Hapytab Tablet (Extended Release) 50 mg is an antidepressant agent and SNRI used for the treatment of major depressive disorders in adults.

Hapytab Tablet (Extended Release) 50 mg is indicated for the treatment of major depressive disorder in adults.

• Hot Flushes
• Major Depressive Disorder (MDD)

Hapytab Tablet (Extended Release) 50 mg is a selective serotonin and norepinephrine reuptake inhibitor. It lacks significant activity on muscarinic-cholinergic, H₁-histaminergic, or α₁-adrenergic receptors in vitro. Hapytab Tablet (Extended Release) 50 mg does not appear to exert activity against calcium, chloride, potassium and sodium ion channels and also lacks monoamine oxidase (MAO) inhibitory activity. It was also shown to lack significant activity again the cardiac potassium channel, hERG, in vitro. Compared to other SNRIs, desvenlafaxine undergoes simple metabolism, has a low risk of drug-drug interactions and does not have to be extensively titrated to reach a therapeutic dose.

Hapytab Tablet (Extended Release) 50 mg, the active metabolite of venlafaxine, is a selective serotonin and norepinephrine reuptake inhibitor. Hapytab Tablet (Extended Release) 50 mg inhibits neurotransmitter reuptake in serotonin, norepinephrine, and dopamine transporters. Hapytab Tablet (Extended Release) 50 mg inhibits serotonin transporters with 10 times the affinity of norepinephrine transporters, and dopamine transporters with the lowest affinity. In vitro, desvenlafaxine has no inhibition of monoamine oxidase, and almost no affinity for muscarinic, cholinergic, H1-histaminergic, and alpha1-adrenergic receptors.

Oral bioavailability is approximately 80% and is unaffected by food. Peak plasma concentration is reached in 7.5 hours.

3.4L/kg.

Protein binding is 30% and this is independent of drug concentration.

Hapytab Tablet (Extended Release) 50 mg is mainly excreted in the urine. 45% of the dose is unchanged in the urine, 19% is excreted as a glucuronide metabolite, and 4. No dosage adjustment is necessary for gender, ethnicity, food, or combination with other psychotropics.

The mean terminal half life is 11.1 hours and may be prolonged in patients with renal and/or moderate to severe hepatic impairment.

Hapytab Tablet (Extended Release) 50 mg is excreted in breast milk and as a result, nursing mothers must either stop the drug or stop breast feeding depending on the risks and benefit to mother and child.

• Avoid alcohol.
• Avoid St. John's Wort.
• Take with or without food. The absorption is unaffected by food.